Glenmark Pharmaceuticals is currently trading at Rs. 579.00, up by 4.70 points or 0.82 % from its previous closing of Rs. 574.30 on the BSE.
The scrip opened at Rs. 576.00 and has touched a high and low of Rs. 580.05 and Rs. 572.05 respectively. So far 3597 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 612.00 on 12-Jul-2013 and a 52 week low of Rs. 467.50 on 26-Apr-2013.
Last one week high and low of the scrip stood at Rs. 604.00 and Rs. 561.40 respectively. The current market cap of the company is Rs. 15576.37 crore.
The promoters holding in the company stood at 48.28 % while Institutions and Non-Institutions held 41.03 % and 10.68 % respectively.
Glenmark Pharmaceuticals through its Swiss subsidiary has received $5 million as milestone payment from Sanofi on a collaboration of its VLA2 (alpha2-beta l) integrin monoclonal antibody. GBR 500 is a first-in-class therapeutic monoclonal antibody for chronic autoimmune disorders.
The company has already received $50 million from Sanofi as an upfront payment in FY2011-12. Hence, the total amount received by Glenmark from Sanofi for its first in class VLA-2 monoclonal antibody is $55 million.
Glenmark’s current portfolio consists of 90 products authorized for distribution in the US marketplace and 53 ANDA’s pending approval with the USFDA. In addition to these internal Filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
